STOCK TITAN
  1. Home
  2. MRTX

Mirati Therapeut (MRTX) Stock Price, News & Analysis

MRTX NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
18 252 sessions, January 23, 2023 to January 23, 2024
Largest daily move
+45.4% close of October 5, 2023
1-year change
+22.5% closing prices, January 23, 2023 to January 23, 2024
5-year change
-9% closing prices, January 23, 2019 to January 23, 2024

Company Description

MRTX has gained 22.5% over the past year. The last closing price was $58.70.

This page collects what Stock Titan holds for MRTX, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
-
-
Last updated:
+22.5%
Performance 1 year
-
Market Cap
-
Shares outstanding

Mirati Therapeut (MRTX) closed at $58.70 on January 23, 2024. Over the past 12 months, the price has gained 22.5%.

See what a $1,000 investment in MRTX would be worth today

MRTX Metrics & Rankings

Month to date
-0.1%
View ranking
YTD
-0.1%
View ranking

Price returns through January 23, 2024. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

View All
-0.24%

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

+0.93%

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure

+0.45%

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

earnings
+0.45%

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

-0.57%

Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)

-5.28%

Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

acquisition

Mirati Therapeut has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include earnings, acquisition, conferences, clinical trial. View all MRTX news →

SEC Filings

View All

No SEC filings available for MRTX.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

Frequently Asked Questions

What is the current quoted price of Mirati Therapeut (MRTX)?

The current quoted price of Mirati Therapeut (MRTX) is $58.7 as of March 22, 2024.